Browse > Article
http://dx.doi.org/10.3857/jkstro.2009.27.2.49

Is Radiotherapy Necessary for Stage 1 Testicular Seminoma?  

Lee, Jung-Ae (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Park, Won (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lim, Do-Hoon (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Ahn, Yong-Chan (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Huh, Seung-Jae (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Yu, Jeong-Il (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Choi, Han-Yong (Departments of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Hyun-Moo (Departments of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Cho, Eun-Yoon (Departments of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Radiation Oncology Journal / v.27, no.2, 2009 , pp. 49-54 More about this Journal
Abstract
Purpose: To report on the clinical outcome of patients with stage I testicular seminoma by postoperative radiotherapy (PORT) or surveillance after radical inguinal orchiectomy. Materials and Methods: This study is a retrospective review of 32 stage I pure seminoma patients treated between 1996 and 2005 at the Samsung Medical Center. Twenty two of the patients were treated by PORT, which was directed at the paraaortic lymphatics with a median dose of 25.2 Gy in 14 fractions for 3 weeks. The 10 remaining patients were managed by surveillance. The median follow-up period was 96 months with a range of 24 to 155 months. Results: Clinically, most patients presented with a testicular mass or discomfort. Two of the patients had a history of undescended testes. Pathologically, 23 of the patients had intratubular germ cell neoplasia with seminoma. Both recurrence-free survival (RFS) and overall survival (OS) rates of patients treated by PORT were 100%. In the control group, 1 of the 10 patients suffered a para-aortic lymph node relapse. The RFS and OS rates of the surveillance group were 88.9% and 100%, respectively. Conclusion: No difference in survival was observed between the two groups. Moreover, symptom recurrence was only observed in 1 patient in the control group. The use of PORT may reduce the risk of relapse. With the availability of effective diagnostic and salvage modalities, surveillance monitoring may be considered for patients in good compliance.
Keywords
Seminoma; Radical orchiectomy; Radiation therapy; Surveillance;
Citations & Related Records
연도 인용수 순위
  • Reference
1 McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003;97:63-70   DOI   ScienceOn
2 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66   DOI   ScienceOn
3 Choo R, Thomas G, Woo T, et al. Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005;61:736-740   DOI   PUBMED   ScienceOn
4 Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999; 17:1146   PUBMED
5 Aparicio J, Germa JR, Garcia del Muro X, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group Study. J Clin Oncol 2005;23:8717-8723   DOI   ScienceOn
6 Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. Apmis 2003;111:76-83   DOI   ScienceOn
7 Jacobsen GK, Mellemgaard A, Engelholm SA, Moller H. Increased incidence of sarcoma in patients treated for testicular seminoma. Eur J Cancer 1993;29A:664-668   PUBMED
8 Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200-1208   DOI   ScienceOn
9 Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-4452   DOI   ScienceOn
10 Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005;366:293-300   DOI   PUBMED   ScienceOn
11 Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640-647   DOI   ScienceOn
12 van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-424   PUBMED